The usual suspects in sudden cardiac death of the young: A focus on inherited arrhythmogenic diseases

Expert Review of Cardiovascular Therapy

Volumn 12, Issue 4, 2014, Pages 499-519

  Mazzanti, Andrea ^a   O'Rourke, Sean ^b   Ng, Kevin ^a   Miceli, Carlotta ^a   Borio, Gianluca ^a   Curcio, Antonio ^a   Esposito, Francesca ^a   Napolitano, Carlo ^a,b   Priori, Silvia G ^a,b,c  

^a IRCCS   (Italy)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

cardiomyopathy; channelopathy; genetic testing; inherited arrhythmogenic diseases; sudden cardiac death

Indexed keywords

ARRHYTHMOGENESIS; BRUGADA SYNDROME; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CHANNELOPATHY; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONGESTIVE CARDIOMYOPATHY; ECG ABNORMALITY; GENETIC ANALYSIS; GENETIC DISORDER; GENETIC VARIABILITY; HEART DISEASE; HEART MUSCLE; HEART RIGHT VENTRICLE DYSPLASIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INHERITED ARRHYTHMOGENIC DISEASE; LIFESTYLE MODIFICATION; LONG QT SYNDROME; PHENOTYPIC VARIATION; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SHORT QT SYNDROME; ST SEGMENT ELEVATION; SUDDEN CARDIAC DEATH; ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHIES; COMPLICATION; DEATH, SUDDEN, CARDIAC; DIFFERENTIAL DIAGNOSIS; DISEASE PREDISPOSITION; GENETICS; PATHOLOGY; PATHOPHYSIOLOGY; TACHYCARDIA, VENTRICULAR;

ARRHYTHMIAS, CARDIAC; BRUGADA SYNDROME; CARDIOMYOPATHIES; DEATH, SUDDEN, CARDIAC; DIAGNOSIS, DIFFERENTIAL; DISEASE SUSCEPTIBILITY; HUMANS; TACHYCARDIA, VENTRICULAR;

EID: 84896985203     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2014.894884     Document Type: Review

References (183)

1. Kong MH, Fonarow GC, Peterson ED, et al. Systematic review of the incidence of sudden cardiac death in the United States. J Am Coll Cardiol 2011;57(7): 794-801
2. Lubinski A, Bissinger A, Boersma L, et al. Determinants of geographic variations in implantation of cardiac defibrillators in the European Society of Cardiology member countries-data from the European Heart Rhythm Association White Book. Europace 2011;13(5):654-62
3. Escobedo LG, Zack MM. Comparison of sudden and nonsudden coronary deaths in the United States. Circulation 1996;93(11): 2033-6
4. Cobb LA, Fahrenbruch CE, Olsufka M, Copass MK. Changing incidence of out-of-hospital ventricular fibrillation, 1980-2000. JAMA 2002;288(23): 3008-13
5. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001;104(18):2158-63
6. Eckart RE, Shry EA, Burke AP, et al. Sudden death in young adults: an autopsy-based series of a population undergoing active surveillance. J Am Coll Cardiol 2011;58(12):1254-61
7. Cross BJ, Estes NA, Link MS. Sudden cardiac death in young athletes and nonathletes. Curr Opin Crit Care 2011; 17(4):328-34
8. United States Census Bureau. 2010 Census Summary File 1. Available from: www.census. gov/2010census/news/press-kits/summary-file- 1.html [Last accessed 1 June 2013]
9. Eurostat: population Satistics. 2010. Available from: www.europa.eu.intcomm/ eurostat [Last accessed 1 June 2013]
10. Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation 2009;119(8):1085-92
11. Corrado D, Basso C, Rizzoli G, et al. Does sports activity enhance the risk of sudden death in adolescents and young adults? J Am Coll Cardiol 2003;42(11):1959-63
12. Van Camp SP, Bloor CM, Mueller FO, et al. Nontraumatic sports death in high school and college athletes. Med Sci Sport Exer 1995;27(5):641-7
13. Holst AG, Winkel BG, Theilade J, et al. Incidence and etiology of sports-related sudden cardiac death in Denmark- implications for preparticipation screening. Heart Rhythm 2010;7(10):1365-71
14. Topaz O, Edwards JE. Pathologic features of sudden death in children, adolescents, and young adults. Chest 1985;87(4):476-82
15. Drory Y, Turetz Y, Hiss Y, et al. Sudden unexpected death in persons less than 40 years of age. Am J Cardiol 1991;68(13): 1388-92
16. Shen WK, Edwards WD, Hammill SC, et al. Sudden unexpected nontraumatic death in 54 young adults: A 30-year population-based study. Am J Cardiol 1995; 76(3):148-52
17. Wisten A, Forsberg H, Krantz P, Messner T. Sudden cardiac death in 15-35-year olds in Sweden during 1992-99. J Intern Med 2002; 252(6):529-36
18. Cho Y, Park T, Yang DH, et al. Arrhythmogenic right ventricular cardiomyopathy and sudden cardiac death in young Koreans. Circ J 2003;67(11): 925-8
19. Eckart RE, Scoville SL, Campbell CL, et al. Sudden death in young adults: A 25-year review of autopsies in military recruits. Ann Intern Med 2004;141(11):829-34
20. Puranik R, Chow CK, Duflou JA, et al. Sudden death in the young. Heart Rhythm 2005;2(12):1277-82
21. di Gioia CR, Autore C, Romeo DM, et al. Sudden cardiac death in younger adults: autopsy diagnosis as a tool for preventive medicine. Hum Pathol 2006;37(7):794-801
22. Papadakis M, Sharma S, Cox S, et al. The magnitude of sudden cardiac death in the young: A death certificate-based review in England and Wales. Europace 2009;11(10): 1353-8
23. Lim Z, Gibbs K, Potts JE, Sanatani S. A review of sudden unexpected death in the young in British Columbia. Can J Cardiol 2010;26(1):22-6
24. Fragkouli K, Vougiouklakis T. Sudden cardiac death: an 11-year postmortem analysis in the region of Epirus, Greece. Pathol Res Pract 2010;206(10):690-4
25. Winkel BG, Holst AG, Theilade J, et al. Nationwide study of sudden cardiac death in persons aged 1-35 years. Eur Heart J 2011;32(8):983-90
26. Margey R, Roy A, Tobin S, et al. Sudden cardiac death in 14- to 35-year olds in Ireland from 2005 to 2007: A retrospective registry. Europace 2011;13(10):1411-18
27. Pilmer CM, Porter B, Kirsh JA, et al. Scope and nature of sudden cardiac death before age 40 in Ontario: A report from the cardiac death advisory committee of the office of the chief coroner. Heart Rhythm 2013; 10(4):517-23
28. Winkel BG, Larsen MK, Berge KE, et al. The prevalence of mutations in KCNQ1, KCNH2, and SCN5A in an unselected national cohort of young sudden unexplained death cases. J Cardiovasc Electrophysiol 2012;23(10):1092-8
29. Mazzanti A, Priori SG. Molecular autopsy for sudden unexplained death? Time to discuss pros and cons. J Cardiovasc Electrophysiol 2012;23(10):1099-102
30. Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995;92(4):785-9
31. Frances RJ. Arrhythmogenic right ventricular dysplasia/cardiomyopathy. A review and update. Int J Cardiol 2006; 110(3):279-87
32. Thiene G, Corrado D, Basso C. Arrhythmogenic right ventricular cardiomyopathy/dysplasia. Orphanet J Rare Dis 2007;2:45
33. Codd MB, Sugrue DD, Gersh BJ, Melton LJ III. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. Circulation 1989;80(3):564-72
34. Schwartz PJ, Stramba-Badiale M, Crotti L, et al. Prevalence of the congenital long-QT syndrome. Circulation 2009;120(18):1761-7
35. Fowler SJ, Priori SG. Clinical spectrum of patients with a Brugada ECG. Curr Opin Cardiol 2009;24(1):74-81
36. Napolitano C, Priori SG, Bloise R. Catecholaminergic polymorphic ventricular tachycardia. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP, editors. Gene reviews. Seattle; WA, USA: 1993
37. Giustetto C, Schimpf R, Mazzanti A, et al. Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol 2011; 58(6):587-95
38. Prevalence of rare diseases: bibliographic data, Orphanet Report Series, Rare Diseases collection, June 2013, Number 1 : Listed in alphabetical order of disease or group of diseases. Available from: www.orpha.net/ orphacom/cahiers/docs/GB/Prevalence- of-rare-diseases-by-alphabetical-list.pdf
39. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003;348(19): 1866-74
40. Geisterfer-Lowrance AA, Kass S, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: A beta cardiac myosin heavy chain gene missense mutation. Cell 1990;62(5): 999-1006
41. Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995;80(5):795-803
42. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011; 8(8):1308-39
43. Mitani Y, Ohta K, Yodoya N, et al. Public access defibrillation improved the outcome after out-of-hospital cardiac arrest in school-age children: A nationwide, population-based, Utstein registry study in Japan. Europace 2013;15(9):1259-66
44. Priori SG, Wilde AA, Horie M, et al. HRS/ EHRA/APHRS Expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromesexpert consensus statement on inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm 2013;e75-e106
45. Earle N, Crawford J, Smith W, et al. Community detection of long QT syndrome with a clinical registry: an alternative to ECG screening programs? Heart Rhythm 2013;10(2):233-8
46. Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation 2002;105(11): 1342-7
47. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002; 106(1):69-74
48. Priori SG, Gasparini M, Napolitano C, et al. Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. J Am Coll Cardiol 2012;59(1):37-45
49. Mazzanti A, Kanthan A, Monteforte N. Novel insights in the natural history of short QT syndrome. J Am Coll Cardiol 2013. [Epub ahead of print]
50. Bai R, Napolitano C, Bloise R, et al. Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing. Circ Arrhythm Electrophysiol 2009;2(1):6-15
51. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: A position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008;29(2):270-6
52. Maron BJ. Sudden death in young athletes. N Engl J Med 2003;349(11):1064-75
53. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiov Surg 2011; 142(6):1303-38
54. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J 2010;31(7): 806-14
55. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10(10): 933-89
56. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline update for implantation of cardiac pacemakers and antiarrhythmia devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;51(21):e1-62
57. Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/ HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2013;127(3):e283-352
58. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33(14):1787-847
59. al-Mahdawi S, Chamberlain S, Chojnowska L, et al. The electrocardiogram is a more sensitive indicator than echocardiography of hypertrophic cardiomyopathy in families with a mutation in the MYH7 gene. Br Heart J 1994;72(2): 105-11
60. Pelliccia A, Di Paolo FM, Quattrini FM, et al. Outcomes in athletes with marked ECG repolarization abnormalities. N Engl J Med 2008;358(2):152-61
61. Gomes J, Finlay M, Ahmed AK, et al. Electrophysiological abnormalities precede overt structural changes in arrhythmogenic right ventricular cardiomyopathy due to mutations in desmoplakin-A combined murine and human study. Eur Heart J 2012;33(15):1942-53
62. Gimeno JR, Lacunza J, Garcia-Alberola A, et al. Penetrance and risk profile in inherited cardiac diseases studied in a dedicated screening clinic. Am J Cardiol 2009;104(3):406-10
63. Michels M, Soliman OI, Phefferkorn J, et al. Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers. Eur Heart J 2009;30(21): 2593-8
64. Mestroni L, Rocco C, Gregori D, et al. Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. J Am Coll Cardiol 1999;34(1):181-90
65. Quarta G, Muir A, Pantazis A, et al. Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria. Circulation 2011;123(23):2701-9
66. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004;363(9424): 1881-91
67. Katz A. Physiology of the heart. Lippincott Williams & Wilkins, PA, USA; 2010
68. Moak JP, Kaski JP. Hypertrophic cardiomyopathy in children. Heart 2012; 98(14):1044-54
69. Jacoby D, McKenna WJ. Genetics of inherited cardiomyopathy. Eur Heart J 2012;33(3):296-304
70. Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis 1985;28(1):1-83
71. Critoph C, Elliot P. Hypertrophic cardiomyopathy. Cardiac Electrophysiol Clin 2010;2(4):587-98
72. Varnava AM, Elliott PM, Sharma S, et al. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart 2000;84(5):476-82
73. Elliott PM, Gimeno JR, Thaman R, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart 2006;92(6):785-91
74. Spirito P, Maron BJ, Bonow RO, Epstein SE. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol 1987;60(1): 123-9
75. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006;48(5): e247-346
76. Watkins H, Rosenzweig A, Hwang DS, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992;326(17):1108-14
77. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/ European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003; 24(21):1965-91
78. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985;53(4):412-16
79. Marcus FI, Fontaine GH, Guiraudon G, et al. Right ventricular dysplasia: A report of 24 adult cases. Circulation 1982;65(2): 384-98
80. Sen-Chowdhry S, Morgan RD, Chambers JC, McKenna WJ. Arrhythmogenic cardiomyopathy: etiology, diagnosis, and treatment. Ann Rev Med 2010;61:233-53
81. Norman M, Simpson M, Mogensen J, et al. Novel mutation in desmoplakin causes arrhythmogenic left ventricular cardiomyopathy. Circulation 2005;112(5): 636-42
82. Elliott P, O'Mahony C, Syrris P, et al. Prevalence of desmosomal protein gene mutations in patients with dilated cardiomyopathy. Circ Cardiovasc Genet 2010;3(4):314-22
83. Tabib A, Loire R, Chalabreysse L, et al. Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with arrhythmogenic right ventricular cardiomyopathy and/or dysplasia. Circulation 2003;108(24):3000-5
84. Sen-Chowdhry S, Syrris P, Ward D, et al. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation 2007; 115(13):1710-20
85. Saffitz JE. The pathobiology of arrhythmogenic cardiomyopathy. Ann Rev Pathol 2011;6:299-321
86. Coonar AS, Protonotarios N, Tsatsopoulou A, et al. Gene for arrhythmogenic right ventricular cardiomyopathy with diffuse nonepidermolytic palmoplantar keratoderma and woolly hair (Naxos disease) maps to 17q21. Circulation 1998;97(20):2049-58
87. McKoy G, Protonotarios N, Crosby A, et al. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet 2000;355(9221): 2119-24
88. Norgett EE, Hatsell SJ, Carvajal-Huerta L, et al. Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. Hum Mol Genet 2000;9(18): 2761-6
89. Syrris P, Ward D, Asimaki A, et al. Clinical expression of plakophilin-2 mutations in familial arrhythmogenic right ventricular cardiomyopathy. Circulation 2006;113(3): 356-64
90. Xu T, Yang Z, Vatta M, et al. Compound and digenic heterozygosity contributes to arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2010; 55(6):587-97
91. Rigato I, Bauce B, Rampazzo A, et al. Compound and digenic heterozygosity predicts life-time arrhythmic outcome and sudden cardiac death in desmosomal gene-related arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc Genet 2013;6(6):533-42
92. Dalal D, Nasir K, Bomma C, et al. Arrhythmogenic right ventricular dysplasia: A United States experience. Circulation 2005;112(25):3823-32
93. Peters S, Trummel M, Meyners W. Prevalence of right ventricular dysplasia-cardiomyopathy in a non-referral hospital. Int J Cardiol 2004;97(3):499-501
94. Nava A, Bauce B, Basso C, et al. Clinical profile and long-term follow-up of 37 families with arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2000;36(7):2226-33
95. Hamid MS, Norman M, Quraishi A, et al. Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. J Am Coll Cardiol 2002;40(8):1445-50
96. Kirchhof P, Fabritz L, Zwiener M, et al. Age- and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. Circulation 2006;114(17):1799-806
97. James CA, Bhonsale A, Tichnell C, et al. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathyassociated desmosomal mutation carriers. J Am Coll Cardiol 2013;62(14):1290-7
98. Corrado D, Basso C, Pilichou K, Thiene G. Molecular biology and clinical management of arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart 2011; 97(7):530-9
99. Paul M, Wichter T, Fabritz L, et al. Arrhythmogenic right ventricular cardiomyopathy: an update on pathophysiology, genetics, diagnosis, and risk stratification. Herzschrittmacherther Elektrophysiol 2012;23(3):186-95
100. Calkins H. Arrhythmogenic right-ventricular dysplasia/cardiomyopathy. Curr Opin Cardiol 2006;21(1):55-63
101. Wichter T, Borggrefe M, Haverkamp W, et al. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation 1992;86(1): 29-37
102. Marcus GM, Glidden DV, Polonsky B, et al. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: A report from the North American ARVC Registry. J Am Coll Cardiol 2009;54(7):609-15
103. Mestroni L, Maisch B, McKenna WJ, et al. Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J 1999;20(2): 93-102
104. Baig MK, Goldman JH, Caforio AL, et al. Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease. J Am Coll Cardiol 1998;31(1):195-201
105. Hershberger RE, Parks SB, Kushner JD, et al. Coding sequence mutations identified in MYH7, TNNT2, SCN5A, CSRP3, LBD3, and TCAP from 313 patients with familial or idiopathic dilated cardiomyopathy. Clin Transl Sci 2008;1(1): 21-6
106. Arbustini E, Pilotto A, Repetto A, et al. Autosomal dominant dilated cardiomyopathy with atrioventricular block: A lamin A/C defect-related disease. J Am Coll Cardiol 2002;39(6):981-90
107. van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol 2012;59(5):493-500
108. Mahon NG, Murphy RT, MacRae CA, et al. Echocardiographic evaluation in asymptomatic relatives of patients with dilated cardiomyopathy reveals preclinical disease. Ann Intern Med 2005;143(2): 108-15
109. Kamisago M, Sharma SD, DePalma SR, et al. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 2000;343(23):1688-96
110. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994; 331(23):1564-75
111. Di Lenarda A, Secoli G, Perkan A, et al. Changing mortality in dilated cardiomyopathy. The Heart Muscle Disease Study Group. Br Heart J 1994;72(6 Suppl): S46-51
112. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999; 353(9146):9-13
113. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341(10):709-17
114. Zecchin M, Di Lenarda A, Gregori D, et al. Are nonsustained ventricular tachycardias predictive of major arrhythmias in patients with dilated cardiomyopathy on optimal medical treatment? Pacing Clin Electrophysiol 2008;31(3): 290-9
115. Disertori M, Quintarelli S, Mazzola S, et al. The need to modify patient selection to improve the benefits of implantable cardioverter-defibrillator for primary prevention of sudden death in non-ischaemic dilated cardiomyopathy. Europace 2013;15(12):1693-701
116. Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006;113(14): 1807-16
117. Schwartz PJ, Priori SG, Napolitano C. The long QT syndrome. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology form cell to bedside. WB Saunders; Philadelphia, PA, USA: 2000. p. 597-615
118. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J 1957;54(1): 59-68
119. Tranebjaerg L, Bathen J, Tyson J, Bitner-Glindzicz M. Jervell and Lange-Nielsen syndrome: A Norwegian perspective. Am J Med Genet 1999;89(3): 137-46
120. Wang Q, Shen J, Splawski I, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995;80(5):805-11
121. Wang Q, Curran ME, Splawski I, et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet 1996;12(1): 17-23
122. Dessertenne F, Coumel P, Fabiato A. [Ventricular fibrillation and twisted peaks]. Presse Med 1969;77(6):193-6
123. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001;103(1):89-95
124. Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation 1991;84(3):1136-44
125. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 2004;292(11):1341-4
126. Spazzolini C, Mullally J, Moss AJ, et al. Clinical implications for patients with long QT syndrome who experience a cardiac event during infancy. J Am Coll Cardiol 2009;54(9):832-7
127. Schwartz PJ, Crotti L. QTc behavior during exercise and genetic testing for the long-QT syndrome. Circulation 2011;124(20):2181-4
128. Liu JF, Jons C, Moss AJ, et al. Risk factors for recurrent syncope and subsequent fatal or near-fatal events in children and adolescents with long QT syndrome. J Am Coll Cardiol 2011;57(8):941-50
129. Zhang L, Timothy KW, Vincent GM, et al. Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes. Circulation 2000;102(23): 2849-55
130. Zareba W, Moss AJ, Schwartz PJ, et al. Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med 1998;339(14): 960-5
131. Moss AJ, Shimizu W, Wilde AA, et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation 2007; 115(19):2481-9
132. Shimizu W, Moss AJ, Wilde AA, et al. Genotype-phenotype aspects of type 2 long QT syndrome. J Am Coll Cardiol 2009; 54(22):2052-62
133. Shimizu W, Horie M, Ohno S, et al. Mutation site-specific differences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome: multicenter study in Japan. J Am Coll Cardiol 2004;44(1):117-25
134. Moss AJ, Zareba W, Kaufman ES, et al. Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-gorelated gene potassium channel. Circulation 2002;105(7):794-9
135. Crotti L, Spazzolini C, Schwartz PJ, et al. The common long-QT syndrome mutation KCNQ1/A341V causes unusually severe clinical manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification. Circulation 2007;116(21):2366-75
136. The credible source for information on medicines. Available from: www.qtdrugs.org
137. Schwartz PJ, Spazzolini C, Crotti L. All LQT3 patients need an ICD: true or false? Heart Rhythm 2009;6(1):113-20
138. Ruan Y, Liu N, Bloise R, et al. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation 2007; 116(10):1137-44
139. Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation 1995;92(12): 3381-6
140. Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation 2004;109(15):1826-33
141. Gaita F, Giustetto C, Bianchi F, et al. Short QT Syndrome: A familial cause of sudden death. Circulation 2003;108(8):965-70
142. Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007;115(4): 442-9
143. Deo M, Ruan Y, Pandit SV, et al. KCNJ2 mutation in short QT syndrome 3 results in atrial fibrillation and ventricular proarrhythmia. Proc Natl Acad Sci USA 2013;110(11):4291-6
144. Giustetto C SC, Giachino D, Antzelevitch C, Gaita F. Short QT syndrome. Cardiogenetics 2011;1(Suppl 1): e5
145. Rautaharju PM, Surawicz B, Gettes LS, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval. Circulation 2009;119(10):e241-50
146. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992;20(6):1391-6
147. Gehi AK, Duong TD, Metz LD, et al. Risk stratification of individuals with the Brugada electrocardiogram: A meta-analysis. J Cardiovasc Electrophysiol 2006;17(6): 577-83
148. Bezzina CR, Shimizu W, Yang P, et al. Common sodium channel promoter haplotype in asian subjects underlies variability in cardiac conduction. Circulation 2006;113(3):338-44
149. Di Diego JM, Cordeiro JM, Goodrow RJ, et al. Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation 2002; 106(15):2004-11
150. Shimizu W, Matsuo K, Kokubo Y, et al. Sex hormone and gender difference-role of testosterone on male predominance in Brugada syndrome. J Cardiovasc Electrophysiol 2007;18(4):415-21
151. Mizusawa Y, Wilde AA. Brugada syndrome. Circ Arrhythm Electrophysiol 2012;5(3): 606-16
152. Antzelevitch C, Brugada R. Fever and Brugada syndrome. Pacing Clin Electrophysiol 2002;25(11):1537-9
153. Ikeda T, Abe A, Yusu S, et al. The full stomach test as a novel diagnostic technique for identifying patients at risk of Brugada syndrome. J Cardiovasc Electrophysiol 2006;17(6):602-7
154. Ohkubo K, Nakai T, Watanabe I. Alcohol-induced ventricular fibrillation in a case of Brugada syndrome. Europace 2013; 15(7):1058
155. Matsuo K, Kurita T, Inagaki M, et al. The circadian pattern of the development of ventricular fibrillation in patients with Brugada syndrome. Eur Heart J 1999;20(6): 465-70
156. Safe drug use and the Brudga syndrome. Available from: www.brugadadrugs.org
157. Paul M, Gerss J, Schulze-Bahr E, et al. Role of programmed ventricular stimulation in patients with Brugada syndrome: A meta-analysis of worldwide published data. Eur Heart J 2007;28(17):2126-33
158. Morita H, Kusano KF, Miura D, et al. Fragmented QRS as a marker of conduction abnormality and a predictor of prognosis of Brugada syndrome. Circulation 2008; 118(17):1697-704
159. Meregalli PG, Tan HL, Probst V, et al. Type of SCN5A mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathies. Heart Rhythm 2009;6(3): 341-8
160. Maury P, Hocini M, Haissaguerre M. Electrical storms in Brugada syndrome: review of pharmacologic and ablative therapeutic options. Indian Pacing Electrophysiol J 2005;5(1):25-34
161. Belhassen B, Viskin S, Fish R, et al. Effects of electrophysiologic- guided therapy with Class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome. J Cardiovasc Electrophysiol 1999;10(10): 1301-12
162. Belhassen B, Glick A, Viskin S. Excellent long-term reproducibility of the electrophysiologic efficacy of quinidine in patients with idiopathic ventricular fibrillation and Brugada syndrome. Pacing Clin Electrophysiol 2009;32(3):294-301
163. Marquez MF, Bonny A, Hernandez-Castillo E, et al. Long-term efficacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an implantable cardioverterdefibrillator: A case series and literature review. Heart Rhythm 2012;9(12): 1995-2000
164. Viskin S. A prospective trial of empiric quinidine therapy for asymptomatic Brugada syndrome. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2008.NLM Identifier: NCT00789165 Available from: http:// clinicaltrials.gov/showNCT00789165 [Last accessed 1 June 2013]
165. Viskin S, Wilde AA, Guevara-Valdivia ME, et al. Quinidine, a life-saving medication for Brugada syndrome, is inaccessible in many countries. J Am Coll Cardiol 2013;61(23): 2383-7
166. Nademanee K, Veerakul G, Chandanamattha P, et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation 2011;123(12): 1270-9
167. Coumel P. Catecholamine-induced severe ventricular arrhythmias with Adams-Stokes syndrome in children: A report of four cases. Br Heart J 1978;40(suppl):28-37
168. Leenhardt A, Glaser E, Burguera M, et al. Short-coupled variant of torsade de pointes. A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias. Circulation 1994;89(1): 206-15
169. Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001;103(2):196-200
170. Lahat H, Pras E, Olender T, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 2001;69(6):1378-84
171. Priori SG, Corr PB. Mechanisms underlying early and delayed afterdepolarizations induced by catecholamines. Am J Physiol 1990;258(6 Pt 2):H1796-805
172. Liu N, Colombi B, Memmi M, et al. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model. Circ Res 2006;99(3):292-8
173. Postma AV, Denjoy I, Hoorntje TM, et al. Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ Res 2002; 91(8):e21-6
174. Leenhardt A, Lucet V, Denjoy I, et al. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 1995;91(5): 1512-19
175. Postma AV, Denjoy I, Kamblock J, et al. Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. J Med Genet 2005;42(11):863-70
176. Aizawa Y, Komura S, Okada S, et al. Distinct U wave changes in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT). Intl Heart J 2006; 47(3):381-9
177. Marjamaa A, Hiippala A, Arrhenius B, et al. Intravenous epinephrine infusion test in diagnosis of catecholaminergic polymorphic ventricular tachycardia. J Cardiovasc Electrophysiol 2012;23(2):194-9
178. van der Werf C, Nederend I, Hofman N, et al. Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives. Circ Arrhythm Electrophysiol 2012;5(4):748-56
179. Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation 2009; 119(18):2426-34
180. Odero A, Bozzani A, De Ferrari GM, Schwartz PJ. Left cardiac sympathetic denervation for the prevention of life-threatening arrhythmias: the surgical supraclavicular approach to cervicothoracic sympathectomy. Heart Rhythm 2010;7(8): 1161-5
181. Kannankeril P. A prospective randomized crossover trial of oral flecainide for Catecholaminergic polymorphic ventricular tachycardia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2010.NLM Identifier: NCT01117454 Available from: http:// clinicaltrials.gov/ showNCT01117454 [Last accessed 1 June 2013]
182. Denegri M, Avelino-Cruz JE, Boncompagni S, et al. Viral gene transfer rescues arrhythmogenic phenotype and ultrastructural abnormalities in adult calsequestrin-null mice with inherited arrhythmias. Circ Res 2012;110(5):663-8
183. Priori SG, Pandit SV, Rivolta I, Berenfeld O. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res 2005;96: 800-7